All News

Virtually every source of income from patient care to ancillary services is being cut for all specialty physicians, not just urologists.

In men with castration-resistant prostate cancer and symptomatic bone metastases, the investigational radiopharmaceutical radium-223 (Alpharadin) improved overall survival by 30% and time to first skeletal-related event by 39% compared with placebo.

In stress continent women, prophylactic placement of a midurethral sling at the time of vaginal prolapse repair significantly decreases the development of bothersome urinary incontinence, even after allowing for delayed incontinence intervention.

We once again approach the end of the year with the American Medical Association, many legislators, and Health and Human Services Secretary Kathleen Sebelius calling for a permanent fix to the sustainable growth rate formula, with no action by Congress.

Placing a patient in a "prone-flexed" position offers a number of benefits for percutaneous nephrolithotomy.

Statin use in patients with hyperlipidemia appears to protect against urinary stone formation.

The newest urology products and services from Eli Lilly and Co., Watson Pharmaceuticals, Inc., BK Medical, Olympus America, Inc., Henry Schein MicroMD, American Medical Systems, and Segasist Technologies.

For the protection and promotion of urologic patients and practices, we must break down artificial barriers that impede progress.

Astellas Pharma, Inc, has announced the receipt of a letter from the FDA indicating that it accepted for filing the new drug application for mirabegron (YM178) and initiated a substantive review.

The use of multiple medications is associated with increased severity of erectile dysfunction, say researchers from Kaiser Permanente Los Angeles Medical Center.

Dendreon Corp. has announced that the Centers for Medicare & Medicaid Services has updated its coverage policy to now cover the infusion costs associated with the administration of the advanced prostate cancer immunotherapy sipuleucel-T (Provenge).

Treatment with the RANK ligand inhibitor denosumab (XGEVA) is effective at delaying the development of bone metastases in men with nonmetastatic castration-resistant prostate cancer, according to a recent multicenter study.

An international research team has discovered a genetic Achilles' heel in neuroendocrine prostate cancer-a vulnerability that researchers say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

Pacific Urology and Diablo Valley Oncology and Hematology Medical Group, both located in Contra Costa County in California, are merging to form a 13-physician group.

Kidney transplants performed using organs from live donors over the age of 70 years are safe for both donors and recipients, according to a recent study.

Prostate cancer patients who undergo radical prostatectomy achieve better results at teaching hospitals than at non-academic medical institutions, according to the findings of an international study led by researchers at Henry Ford Hospital?s Vattikuti Urology Institute, Detroit.

Aristolochic acid, a plant component used in herbal remedies, appears to lead to kidney failure and urothelial cell carcinomas (UCC) in individuals exposed to the toxin, an international group of researchers reports.

The U.S. Preventive Services Task Force (USPTF) announced it was no longer recommending the PSA test to screen healthy men for prostate cancer, but experts say the impact this recommendation could have on health insurance coverage and treatment decisions remains unclear. While insurers are likely to take their time issuing formal coverage decisions, the AUA and other urology organizations have been quick to respond to the recommendation.

Glenn M. Preminger, MD, has been appointed chief of urologic surgery at Duke University Medical Center, Durham, NC.

Men who take a daily vitamin E supplement face an increased risk of prostate cancer, according to a new report summarizing the latest results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

The Alliance of Specialty Medicine soundly rejected MedPAC?s approval of a recommendation that Congress reform the Medicare reimbursement system by reducing reimbursements to specialists by 5.9% per year for 3 years while freezing the reimbursement rate for primary care physicians.

Efforts in an increasing number of states to not provide Medicaid insurance coverage for male circumcision, as well as an attempted ballot initiative in San Francisco earlier this year to ban male circumcision in newborns and young boys, are unwarranted, say infectious disease experts from Johns Hopkins University, Baltimore.

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington, Seattle have discovered a number of potential key drivers?recurrent genetic mistakes?common to advanced prostate cancer that may contribute to disease progression.

Men over 75 years of age are being undertreated for prostate cancer, while patients with a single comorbid condition such as peripheral vascular disease are being overtreated and doing much more poorly than expected, say researchers from UCLA?s Jonsson Comprehensive Cancer Center.

The future of patient-centered urologic care depends on collaboration with allied advocacy affiliates.

This list of National Institutes of Health trials is derived from the NIH's database and includes phase III and IV bladder cancer trials and phase II overactive bladder trials. This list is current as of Sept. 15, 2011.

Near infrared fluorescence imaging of intravenous indocyanine green during robot-assisted laparoscopic partial nephrectomy can accurately identify the renal vasculature and successfully differentiate tumor from surrounding parenchyma.

Serum testosterone concentration rises in a predictable manner after implantation of extended-release testosterone pellets (Testopel), and the dose response is not impacted by the patient's body mass index.